MolecuLight Showcases Advanced Wound Care Imaging at 2025 CAMPS Meeting

"Our technology addresses a critical need in wound care by providing clinicians with the ability to see what they otherwise couldn't," said Anil Amlani, CEO at MolecuLight. "By visualizing bacterial presence, we can help support the efficacy of advanced therapies such as CAMPs, improve patient outcomes, and ultimately reduce the burden of chronic wounds." "Our technology addresses a critical need in wound care by providing clinicians with the ability to see what they otherwise couldn't," said...

"Our technology addresses a critical need in wound care by providing clinicians with the ability to see what they otherwise couldn't," said Anil Amlani, CEO at MolecuLight. "By visualizing bacterial presence, we can help support the efficacy of advanced therapies such as CAMPs, improve patient outcomes, and ultimately reduce the burden of chronic wounds."

The proposed new LCD language for skin substitutes emphasizes the importance of comprehensive wound assessment and documentation. MolecuLight's comprehensive wound imaging and measurement devices directly support these requirements by providing:

"MolecuLight's ability to provide real-time, objective data aligns perfectly with the evolving standards for wound care documentation and treatment," added Anil Amlani, "We are excited to showcase how our technology can help healthcare providers meet the requirements of the proposed LCD language and deliver optimal patient care."

Visit MolecuLight at the 2025 CAMPS Meeting

Attendees of the 2025 CAMPS Meeting are invited to visit MolecuLight at booth #21 to experience the technology firsthand and learn more about its applications not only with CAMPs, but and across the entire wound care continuum.

Attendees are also encouraged to attend the breakout session, "How to ensure optimal outcomes with CAMPs" (Feb 28^th, 11:25 AM - 12:45 PM), where MolecuLight will be discussed as an innovative technology to improve would bed preparation for optimized CAMPs outcomes.

About MolecuLight

MolecuLight Inc., is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X^® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

For sales, media or other inquiries or further information, please contact

Hunter Zudans
Director of Marketing
MolecuLight Inc.
T. +1.484.682.7580
[email protected]
www.moleculight.com

Photo - https://mma.prnewswire.com/media/2630037/MolecuLight_MolecuLight_Showcases_Advanced_Wound_Care_Imaging_at.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-showcases-advanced-wound-care-imaging-at-2025-camps-meeting-302388126.html